Evidence map›Paper›PMID 35171675›Full record

ArticleScience advances2022

Personalized chordoma organoids for drug discovery studies.

Ahmad Al Shihabi, Ardalan Davarifar, Huyen Thi Lam Nguyen, Nasrin Tavanaie, Scott D Nelson, Jane Yanagawa, Noah Federman, Nicholas Bernthal, Francis Hornicek, Alice Soragni

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 70 citations in OpenAlex.

  1. New developments and applications of human organoids.Nature reviews. Molecular cell biology · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. The Use of Organoid Cultures in Advancing Nutrition Research.Advances in nutrition (Bethesda, Md.) · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Label-Free 3D Photoacoustic Imaging of Tumor Organoids for Volumetric Drug Screening.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ahmad Al ShihabiDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-4736-6926
Ardalan DavarifarDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-8779-2893
Huyen Thi Lam NguyenDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0001-6291-6792
Nasrin TavanaieDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Scott D NelsonDepartment of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-8435-5065
Jane YanagawaDivision of Thoracic Surgery, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Noah FedermanDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Nicholas BernthalDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-3338-5878
Francis HornicekDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Alice SoragniDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-6634-2885
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
The Evolution of Sarcoma Drug Sensitivity through Time and SpaceR01CA244729 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BOUTROS, PAUL CHRISTOPHER, SORAGNI, ALICE · 2020 to 2024
$3.4M
Evaluating the impact of genetic ancestry on the biology and drug response profile of pheochromocytoma and paraganglioma-derived organoid modelsR01CA264248 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAHIA, PATRICIA LEAL, SORAGNI, ALICE · 2021 to 2025
$3.2M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA244729NCI NIH HHS R01 CA264248
6 · The paper itself

Abstract

Chordomas are rare tumors of notochordal origin, most commonly arising in the sacrum or skull base. Chordomas are considered insensitive to conventional chemotherapy, and their rarity complicates running timely and adequately powered trials to identify effective treatments. Therefore, there is a need for discovery of novel therapeutic approaches. Patient-derived organoids can accelerate drug discovery and development studies and predict patient responses to therapy. In this proof-of-concept study, we successfully established organoids from seven chordoma tumor samples obtained from five patients presenting with tumors in different sites and stages of disease. The organoids recapitulated features of the original parent tumors and inter- as well as intrapatient heterogeneity. High-throughput screenings performed on the organoids highlighted targeted agents such as PI3K/mTOR, EGFR, and JAK2/STAT3 inhibitors among the most effective molecules. Pathway analysis underscored how the NF-κB and IGF-1R pathways are sensitive to perturbations and potential targets to pursue for combination therapy of chordoma.

Indexed as

Antineoplastic AgentsChordomaDrug DiscoveryHumansOrganoidsTreatment OutcomeAntineoplastic Agents

Identifiers

PMID35171675
PMCPMC8849332
OpenAlexW4220764623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.